公司資料
Merck 股價、新聞與催化劑
- 股票代碼:
- MRK
- 交易所:
- NYSE
- 產業:
- Oncology, Immunotherapy, Vaccines
- 所在地:
- United States
股票表現
143.81 USD (-1.03%)
收盤價
最後更新: 2026年10月1日
286B USD
市值
股價為何變動
截至 2026年10月1日，MRK 下跌 1.03%，收於 $143.81。目前新聞監測窗口內未發現新的同公司新聞。
公司概覽
Diversified Human and Animal Health Company
Merck, known as MSD outside the United States and Canada, is a global biopharmaceutical company with businesses in prescription medicines, vaccines, and animal health. Its human-health research spans oncology, infectious disease, vaccines, cardiometabolic and respiratory disease, immunology, neuroscience, and ophthalmology.
Oncology and the KEYTRUDA Franchise
Oncology is anchored by KEYTRUDA and subcutaneous KEYTRUDA QLEX, which are used across a broad range of solid tumors and hematologic malignancies. Merck is extending the franchise through earlier-stage treatment, perioperative regimens, and combinations with antibody-drug conjugates and targeted therapies. Its broader oncology pipeline includes sacituzumab tirumotecan, the personalized cancer vaccine intismeran autogene, KRAS inhibitor calderasib, and BCR::ABL1 inhibitor MK-4208.
Vaccines and Infectious Diseases
Merck has a large vaccine franchise spanning human papillomavirus, pneumococcal disease, respiratory syncytial virus, and other infectious diseases. The HIV portfolio combines approved daily treatment with investigational weekly and monthly approaches, including once-weekly islatravir and lenacapavir and once-monthly oral PrEP candidate alimatravir.
Cardiometabolic and Respiratory Medicines
The cardiometabolic portfolio includes WINREVAIR for pulmonary arterial hypertension and LIPFENDRA, an oral PCSK9 inhibitor for hypercholesterolemia. The acquisition of Verona Pharma added OHTUVAYRE for chronic obstructive pulmonary disease, expanding Merck's presence in respiratory medicine alongside a pipeline of cardiovascular and metabolic programs.
Immunology Pipeline
Merck is developing tulisokibart, an anti-TL1A antibody, across ulcerative colitis and other immune-mediated diseases. The program is part of a broader effort to build an immunology franchise through internally developed biologics and externally sourced assets that target inflammatory pathways with potential applications across gastrointestinal, dermatologic, and systemic autoimmune disorders.
Animal Health Business
Merck Animal Health markets medicines, vaccines, identification technologies, and health-management products for livestock and companion animals. The business provides an additional source of diversification and has expanded through acquisitions such as TARGAN, which added automated poultry vaccination and biodevice capabilities.
未來催化劑
- Planned global regulatory submissions for the once-weekly oral islatravir/lenacapavir HIV treatment regimen following positive Phase 3 ISLEND-1 and ISLEND-2 results.
- Presentation of full Phase 2 results for tulisokibart in hidradenitis suppurativa at an upcoming medical meeting.
近期新聞
新聞標題由機器翻譯，詳情為英文原文。
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。